Research programme: malaria vaccine - Cytos/WRAIR

Drug Profile

Research programme: malaria vaccine - Cytos/WRAIR

Latest Information Update: 13 May 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Cytos Biotechnology; Walter Reed Army Institute of Research
  • Class
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Suspended Malaria

Most Recent Events

  • 13 May 2014 Research programme: malaria vaccine - Cytos/WRAIR is available for licensing as of 05 May 2014.
  • 18 Aug 2011 Suspended for Malaria in USA (unspecified route)
  • 31 Mar 2011 Early research in Malaria in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top